Chronic Obstructive Pulmonary Diseases : Journal of the COPD Foundation Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD : The GEM 2 Study

Long-acting bronchodilators including muscarinic antagonists are central to the management of patients with COPD. The Glycopyrrolate Effect on syMptoms and lung function (GEM2) study assessed the efficacy and safety of twice-daily glycopyrrolate 15.6μg in patients with moderate-to-severe airflow limitation. This 12-week multicenter, double-blind study randomized (1:1) patients to glycopyrrolate 15.6μg twice daily (b.i.d.) or placebo both delivered via the NeohalerTM device. The primary objective was superiority of glycopyrrolate compared with placebo for forced expiratory volume in 1 second (FEV1) standardized area under curve (AUC) between 0 and 12 hours post dosing (FEV1 AUC0-12h) at week 12. Other outcomes included additional spirometry parameters, health status using St George’s Respiratory Questionnaire (SGRQ), dyspnea via Transition Dyspnea Index (TDI), rescue medication use and COPD symptoms reported by patients via the electronic diary. Safety was also assessed. Of the 432 patients randomized (glycopyrrolate, n=216; placebo, n=216), 96% completed the planned treatment phase. The study met its primary objective (superiority of glycopyrrolate compared with placebo for FEV1 AUC0-12h). Compared with placebo, glycopyrrolate showed significant improvements in lung function parameters (p<0.001). Health status (SGRQ total score and COPD assessment test), rescue medication use and daily total COPD symptom scores were significantly improved with glycopyrrolate versus placebo over 12 weeks. Improvements in dyspnea were observed with glycopyrrolate and placebo although the treatment difference was not statistically significant. Overall, differences in the incidences of adverse events and serious adverse events between the groups were not considered clinically meaningful. No deaths were reported. Twice-daily glycopyrrolate 15.6μg showed statistically significant and clinically meaningful improvements compared with placebo in lung function, COPD symptoms, health status, and rescue medication usage in COPD patients with moderate-to-severe airflow limitation. Clinical Trial Registration: NCT01715298 Abstract

[1]  W. Aronow,et al.  Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use , 2014, Expert opinion on drug safety.

[2]  E. Kerwin,et al.  Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies , 2014, Current medical research and opinion.

[3]  J. Wedzicha,et al.  Minimal clinically important differences in pharmacological trials. , 2014, American journal of respiratory and critical care medicine.

[4]  S. Rennard,et al.  ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients , 2013, Clinical Drug Investigation.

[5]  C. Ulrik.  Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit , 2012, International journal of chronic obstructive pulmonary disease.

[6]  K. Hirata,et al.  Efficacy and safety of once-daily NVA 237 in patients with moderate-to-severe COPD : the GLOW 1 trial , 2012 .

[7]  Marie Westwood,et al.  Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review , 2011, Respiratory research.

[8]  C. Vogelmeier,et al.  Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. , 2010, Pulmonary pharmacology & therapeutics.

[9]  Y Fukuchi,et al.  Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. , 2010, Respiratory medicine.

[10]  C. Vogelmeier,et al.  Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations , 2010, Respiratory research.

[11]  M. Pistolesi,et al.  Outcomes for COPD pharmacological trials: from lung function to biomarkers , 2008, European Respiratory Journal.

[12]  M. Yacoub,et al.  Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea‐pig airways , 1999, British journal of pharmacology.